sampleGLP-1/GCG dual
98%+ · 5mg · Lyophilized
Bulk discount
3+ pcs
€65.55
−5%
5+ pcs
€62.10
−10%
10+ pcs
€58.65
−15%
Discount is applied automatically at checkout.
Enter your email and we'll notify you when it's back:
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ verified — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
3-7 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Cash on delivery
Mazdutide
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
In short
Dual agonist of GLP-1 and glucagon receptors studied in metabolic models for adipose tissue reduction.
Best sellers
Related resources
Ready-to-use starter kit
Mazdutide is a synthetic peptide that functions as a dual agonist for both the glucagon-like peptide-1 (GLP-1) and glucagon receptors. At the molecular level, it combines the activation of GLP-1 pathways involved in appetite regulation with glucagon signaling that stimulates energy expenditure. Scientists are investigating this molecule in laboratory (in vitro) and animal models to analyze its synergistic effects on metabolism. This product is intended strictly for research purposes and is not an approved medication for human use.
Research reagent for laboratory use only. Not a medicine. For medical questions, consult a physician.
Scientific review
Written by
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed by
Борис Маринов
MSc Biochemistry & Molecular Biology
Reviewed on
Mazdutide (IBI362/LY3305677) is a first-in-class dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist, and a synthetic analog of oxyntomodulin. Unlike tirzepatide which targets GIP/GLP-1, mazdutide uniquely combines GLP-1's appetite suppression with glucagon's ability to stimulate thermogenesis and increase energy expenditure. Phase 3 trials (GLORY-1, GLORY-2) have demonstrated up to 20% weight loss, with recent head-to-head trials showing superiority over semaglutide for both glycemic control and weight reduction in patients with type 2 diabetes and obesity.
Dual GLP-1/glucagon agonist (Innovent + Eli Lilly) 18.6% weight loss over 48 weeks (GLORY-1) Glucagon-mediated thermogenic effect Lipid profile improvement
Dual agonist of GLP-1 and glucagon receptors. GLP-1 activation: stimulates insulin release, suppresses glucagon, slows gastric emptying, reduces appetite via hypothalamic signaling. Glucagon activation: increases energy expenditure and thermogenesis, improves hepatic fat metabolism. The dual mechanism provides synergistic weight loss effects while GLP-1 counteracts glucagon's glucose-raising effects.
GLORY-2 trial: 20.1% weight loss with 9mg dose over 60 weeks. 48.7% of non-diabetic participants achieved ≥20% weight reduction - approaching surgical outcomes
Significant reductions in waist circumference, systolic BP (-7.57 mmHg), diastolic BP (-2.98 mmHg), triglycerides (-43%), LDL cholesterol, and uric acid
Exploratory analysis from GLORY-1 showed 80.2% reduction in liver fat content, suggesting potential MASLD/MASH benefits
Dosing
The typical regimens you'll see in the published research - for reference when planning in vitro or in vivo experiments. Not medical advice.
Disclaimer
These are regimens discussed in the research literature, not medical advice. Consult a healthcare provider before use.
Timing
Any time of day, with or without food
[Calculator]
Change water and dose · results update in real time
from product
Visual indicator
Pull to mark 10
10marks
Standard insulin syringe 1 ml (100 marks)
Concentration
2.50mg/ml
Dose volume
0.100ml
U-100 units
10units
Doses per vial
20doses
Recommended needle
29G–30G / 1 ml insulin
Small volume — draw slowly; 30G works for finer precision
Cycle planner: vials for 12 weeks, cost, schedule
Opens full calculator
Results are reference values - for in vitro work. Verify against the published literature for the specific peptide.
[Step by step]
6 steps from a sealed vial to the injection. Plain language.
Peptide vial (5 mg), bacteriostatic water vial, 1 larger syringe (3-5 ml) for drawing water and 1 insulin (1 ml) for doses. Alcohol swabs for sanitizing the caps.
Wash your hands before starting.
Wipe the rubber cap of the water vial with an alcohol swab. Insert the needle, invert the vial and draw exactly 2 ml. Get the exact volume from the calculator.
Larger syringe = smaller error in volume.
Wipe the peptide vial cap. Tilt the vial 45° and release the water SLOWLY down the inner wall. Peptides are fragile — a direct stream onto the powder denatures them.
SLOWLY · DOWN THE WALL · NOT ONTO THE POWDER.
Hold the vial between both palms and swirl slowly. DO NOT shake or flip sharply — peptides break down under mechanical stress.
DON'T SHAKE. Like tea — not like a cocktail.
The powder should fully dissolve. The solution is clear, no visible particles. If cloudy or with sediment — discard (wrong water or bad batch).
Clear = OK. Cloudy = discard.
With the insulin syringe draw the exact marks from the calculator. Swab the skin (abdomen 5 cm around the navel, thigh, or buttock), pinch a fold, insert at 45-90° and inject slowly.
Rotate sites every injection to avoid lipohypertrophy.
Schedule
Any time of day, with or without food
Remove mazdutide vial from freezer/refrigerator and allow to reach room temperature (15-20 minutes)
Clean vial top with alcohol swab using circular motion, allow to air dry completely
Calculate appropriate reconstitution volume based on desired concentration
Draw calculated amount of bacteriostatic water into syringe, remove air bubbles
Insert needle at 45-degree angle against vial wall, NOT directly into powder
Slowly inject BAC water down the side of the vial - drop by drop to prevent foaming
Remove needle and gently swirl vial in circular motion - NEVER shake vigorously
Allow solution to sit 2-3 minutes if cloudiness persists, then swirl gently until completely clear
Final solution should be completely clear and colorless - discard if cloudy or contains particles
Label vial with reconstitution date and concentration
Store reconstituted solution at 2-8°C, use within 30 days
Start with lowest dose and escalate gradually every 4 weeks to minimize GI side effects
GI symptoms (nausea, diarrhea, vomiting) are most common - typically mild-moderate and improve over time
Increased heart rate (5-17 bpm) observed but not associated with cardiac events in trials
Monitor for signs of pancreatitis - severe persistent abdominal pain radiating to back
Caution with personal/family history of medullary thyroid carcinoma or MEN2 syndrome (class warning for agonists)
If taking insulin or sulfonylureas, monitor blood glucose closely and reduce doses as needed
Not recommended during pregnancy or breastfeeding - insufficient safety data
Stay well hydrated, especially during initial weeks when GI symptoms may occur
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
GLORY-1 Phase 3 Trial - NEJM (2025)
610 Chinese adults with obesity/overweight | 48 weeks | 4mg and 6mg doses
First Phase 3 weight management trial showing clinically meaningful weight reductions with once-weekly mazdutide. Both doses achieved significant weight loss vs placebo with favorable safety profile.
View the studyGLORY-2 Phase 3 Trial (2025)
462 Chinese adults with obesity (BMI ≥30) | 60 weeks | 9mg dose
High-dose 9mg mazdutide achieved 20.1% weight loss in non-diabetic participants vs 2.8% placebo. 48.7% achieved ≥20% weight reduction. No plateau observed through week 60.
View the studyDREAMS-3 Phase 3 Trial - Head-to-Head vs Semaglutide (2025)
349 Chinese adults with T2D and obesity | 32 weeks | Mazdutide vs Semaglutide
Mazdutide showed superiority over semaglutide on primary endpoint - 48.0% vs 21.0% achieved HbA1c <7.0% AND ≥10% weight reduction (p<0.0001). Mean HbA1c reduction -2.03% vs -1.84%.
View the studySystematic Review & Meta-Analysis - Frontiers (2024)
7 RCTs | 680 participants | 4-24 weeks | Meta-analysis of efficacy and safety
Overall 6.22% greater weight reduction vs placebo. Non-diabetics: 8.44% reduction. Significant improvements in BP, cholesterol, triglycerides. GI side effects most common but transient.
View the studyPhase 2 T2D Trial - Diabetes Care (2024)
Chinese adults with T2D | 20 weeks | 3mg, 4.5mg, 6mg doses vs placebo and dulaglutide
HbA1c reductions of 1.41-1.67% with mazdutide vs 0.03% placebo. Weight loss up to 7.1% vs 1.4% placebo. 54-73.5% achieved HbA1c <7.0% target.
View the studyPhase 1b High-Dose Safety Trial - eClinicalMedicine (2022)
24 Chinese adults with overweight/obesity | 12 weeks | 9mg and 10mg doses
9mg and 10mg doses were well tolerated with favorable safety profile. 11.7% weight loss at 12 weeks in 9mg cohort. No serious adverse events reported.
View the study
for longevity
for sexual health
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
